Pfizer Inc. (NYSE:PFE) Shares Sold by Providence Wealth Advisors LLC

Providence Wealth Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 3.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 41,343 shares of the biopharmaceutical company’s stock after selling 1,450 shares during the period. Providence Wealth Advisors LLC’s holdings in Pfizer were worth $1,117,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.19 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $142.88 billion, a price-to-earnings ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The stock’s 50-day moving average is $26.12 and its two-hundred day moving average is $26.98. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.